eleclazine

Eleclazine is a small molecule antiarrhythmic drug developed as a selective inhibitor of the cardiac late sodium current (late INa). Its primary mechanism of action is antagonism of the sodium channel protein type 5 subunit alpha, which reduces abnormal prolongation of cardiac repolarization. This effect is particularly relevant in conditions such as Long QT Syndrome Type 3 (LQT3), where increased late sodium current contributes to arrhythmogenesis. Eleclazine was investigated for oral use in several indications including LQT2 Syndrome, Long QT Syndrome (especially LQT3), ischemic heart disease, ventricular arrhythmia, and hypertrophic cardiomyopathy. Clinical trials reached up to Phase III for some indications but development has not progressed to approval[1][2][3][4][5][6].

Other names

Eleclazine [INN]Eleclazina1443211-72-0UNII-PUY08529FKUNII-PUY-08529FKUNII-PUY 08529FK